Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
Introduction The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly because of the lack of convincing evidence on...
Main Authors: | C. Gastaldon, E. Raschi, J. Kane, C. Barbui |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2021-04-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933821004107/type/journal_article |
Similar Items
-
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022-04-01) -
Treating with esketamine nasal, will increase blood pressure?
by: V. Rosello-Molina, et al.
Published: (2021-04-01) -
Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
by: Xiaofeng Lan, et al.
Published: (2023-09-01) -
Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01) -
Esketamine, a new treatment for resistant depression: a systematic review of the literature
by: Mercedes Valtueña García, et al.
Published: (2021-07-01)